" "On January 15, 2015 Unilife entered into a definitive global strategic agreement with AbbVie Inc. for the customization and supply of
its injectable drug delivery systems for use with AbbVie’s drug portfolio. Unilife has been selected by AbbVie as a preferred partner
for the customization and supply of innovative, differentiated drug delivery systems. AbbVie paid $5 million for the exclusive right to
form and enter into a mutually-agreeable development and supply agreement with Unilife to include exclusive access to the Unifill
Finesse™ prefilled syringe and the LISA™ reusable auto-injector for target therapies within AbbVie’s drug portfolio for the treatment
of auto-immune diseases, as well as associated exclusivity fees. The target therapies and conditions for which these systems will be
used are confidential under the terms of the agreement."
I thought that the $5 million was only for the right to negotiate, this sounds like a supply agreement has been reached.
There seems to be a change in the language.